Chimeric Therapeutics (ASX:CHM) completes dose-finding portion of ADVENT-AML Phase 1B trial

October 24, 2024 12:14 PM AEDT | By Sonal Goyal

Chimeric Therapeutics (ASX:CHM) completes dose-finding portion of ADVENT-AML Phase 1B trial — Image source: Company update

Recent News

HMC Capital Expands into Data Centre Sector with Global Switch Acquisi...

Tempest Minerals Discovers High-Grade Magnetite at Yalgoo's Remorse Ta...

HMC Capital Secures $300m for Data Centre Acquisition

CI&T appoints ex-Telstra, NAB, and ANZ exec to drive product-centric i...

Highlights

Chimeric Therapeutics has completed enrolment for ADVENT-AML Phase 1B clinical trial for the dose-finding stage.

In the next phase, the company will enrol newly diagnosed AML (Acute Myeloid Leukemia) patients who are elderly or ineligible for transplantation.

ADVENT-AML is the first study to assess the effectiveness of combination of CORE NKs and standard of care for many AML patients.

Chimeric Therapeutics (ASX:CHM) has successfully completed enrolment for its ADVENT-AML Phase 1B clinical trial in AML for the dose-finding phase, with no dose-limiting toxicities or unexpected safety findings. In the next phase of the study, the company will recruit those patients who are newly diagnosed with AML, elderly or unsuitable for intensive chemotherapy or allogeneic stem cell transplant.

Details of the ADVENT-AML (NCT05834244) Phase 1B clinical trial

Data source: Company update

Following the update, CHM share price has surged by 5.55% to trade at AU$0.009 apiece at the time of drafting on 24 October 2024.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.